VOL. XCIV, NO. 247

* WIDE MOAT STOCKS COMPARISON *

NO ADVICE

Sunday, December 28, 2025

Stock Comparison

Copart, Inc. vs GE HealthCare Technologies Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Copart, Inc.

CPRT · The NASDAQ Global Select Market

Market cap (USD)
SectorIndustrials
CountryUS
Data as of2025-12-28
Moat score
71/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

View full moat analysis >

GE HealthCare Technologies Inc.

GEHC · The Nasdaq Stock Market LLC

Market cap (USD)
SectorHealthcare
CountryUS
Data as of2025-12-22
Moat score
63/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

View full moat analysis >

Side-by-side metrics

Copart, Inc.
GE HealthCare Technologies Inc.
Ticker / Exchange
CPRT - The NASDAQ Global Select Market
GEHC - The Nasdaq Stock Market LLC
Market cap (USD)
n/a
n/a
Sector
Industrials
Healthcare
HQ country
US
US
Primary segment
United States
Imaging
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
n/a
Moderate
Moat score
71 / 100
63 / 100
Moat domains
Network, Supply, Demand, Legal, Financial
Supply, Demand, Network, Legal
Last update
2025-12-28
2025-12-22

Moat coverage

Shared moat types

Service Field NetworkData Workflow LockinCompliance Advantage

Copart, Inc. strengths

Two Sided NetworkBenchmark Pricing Power

GE HealthCare Technologies Inc. strengths

Training Org Change CostsEcosystem ComplementsInstalled Base ConsumablesSupply Chain ControlScope Economies

Segment mix

Copart, Inc. segments

Full profile >

United States

Oligopoly

83%

International

Competitive

17%

GE HealthCare Technologies Inc. segments

Full profile >

Imaging

Oligopoly

45%

Advanced Visualization Solutions (AVS)

Oligopoly

26.1%

Patient Care Solutions (PCS)

Oligopoly

15.9%

Pharmaceutical Diagnostics (PDx)

Oligopoly

12.8%

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.